Lonza Group, reported €2.5 billion divestment plan
19.06.2026 - 13:01:47 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 13:00 CET. Details in the imprint.
Lonza Group (CH0013841017) is again reshaping its portfolio. According to a report from Russian news agency AK&M citing foreign media on 06/19/2026, the Swiss group is exploring a sale of its capsules and health ingredients division valued at about EUR 2.5 billion.
All news and background on Lonza Group
Current reports on Lonza Group stock, from strategy moves to earnings and market valuations, can be found in our dedicated topic section and on the company's investor-relations pages.
Reported asset sale details
AK&M reports that Lonza is working with Bank of America and Centerview Partners to evaluate a potential sale of the capsules and health ingredients unit, with a possible deal value of EUR 2.5 billion.
According to the same report, private equity firms Lone Star, Altaris and One Rock Capital Partners are among potential bidders for the business, which would represent a sizable carve-out in the group's portfolio.
How the move fits the sector picture
The potential sale would continue a trend of European life-science suppliers concentrating on higher-margin contract development and manufacturing services, while divesting more commoditized activities such as standard dosage forms and nutrition ingredients.
For peers like Catalent and Sartorius, investors have recently focused on capital allocation discipline and portfolio focus, and Lonza's reported move would be consistent with this broader sector narrative of sharpening exposure to biologics and complex therapies.
How the company makes money
Lonza's core business is contract development and manufacturing for the pharmaceutical and biotechnology industry, producing biologic drug substances, cell and gene therapies, small-molecule APIs and specialized ingredients for healthcare and personal care customers worldwide.
Where the stock trades today
The shares of Lonza Group (CH0013841017) trade on SIX Swiss Exchange; the latest reliably verified price data were not available at the time of this update, so no current Swiss-franc quote can be stated here.
Key facts on Lonza Group stock
- Company: Lonza Group AG
- ISIN: CH0013841017
- Ticker: LONN
- Venue: SIX Swiss Exchange
- Sector / Industry: Health Care / Life Science Tools & Services
- Index membership: SMI, SPI
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
